Table 1

Baseline Clinical Characteristics

Combo (n = 124)TAXUS (n = 59)p Value
Age (yrs)64.20 ± 9.4864.05 ± 10.490.92
Men89 (71.8%)42 (71.2%)0.93
Smoking/tobacco usage71 (57.3%)28 (47.5%)0.21
Current smoker26 (21.0%)10 (16.9%)0.52
Diabetes mellitus41 (33.1%)22 (37.3%)0.57
Insulin-dependent9 (7.3%)7 (11.9%)0.30
History of hypertension100 (80.6%)45 (76.3%)0.50
History of hyperlipidemia102 (82.3%)43 (72.9%)0.14
Left ventricular ejection fraction (%)63.87 ± 11.93 (119)63.33 ± 11.59 (59)0.77
Premature cardiovascular disease in 1st-degree relative36 (29.0%)23 (39.0%)
Previous congestive heart failure17 (13.7%)6 (10.2%)0.50
Previous MI31 (25.0%)16 (27.1%)0.76
Previous PCI29 (23.4%)12 (20.3%)0.64
Previous CABG4 (3.2%)2 (3.4%)1.00
History of renal insufficiency8 (6.5%)1 (1.7%)0.28
Angina status
 Silent ischemia13 (10.5%)6 (10.2%)0.95
 Stable angina91 (73.4%)43 (72.9%)0.94
  CCS I13 (10.5%)10 (16.9%)0.22
  CCS II60 (48.4%)29 (49.2%)0.92
  CCS III15 (12.1%)4 (6.8%)0.27
  CCS IV3 (2.4%)0 (0.0%)0.55
 Unstable angina20 (16.1%)10 (16.9%)0.89
  Braunwald I6 (4.8%)2 (3.4%)1.00
  Braunwald II8 (6.5%)2 (3.4%)0.50
  Braunwald III6 (4.8%)6 (10.2%)0.21

Values are mean ± SD or n (%). Combo stent (OrbusNeich Medical, Ft. Lauderdale, Florida); Taxus Liberté stent (PES) (Boston Scientific, Natick, Massachusetts).

CABG = coronary bypass surgery; CCS = Canadian Cardiovascular Society; MI = myocardial infarction; PCI = percutaneous coronary intervention.